Know Your Investor: Samsara Biocapital (November’25 Edition)

Shots: Samsara Biocapital is a California-based venture capital and registered investment adviser investing across early to post-IPO stages in healthcare, life sciences, oncology, and digital health, with a portfolio of 70+ companies including Scholar Rock and PepGen The firm made 30 investments across PIPE (43%), Series B (23%), and other rounds, with notable deals such…

ByPrince GiriNovember 5, 2025

INSIGHTS+

Know Your Investor: Cormorant Asset Management (September’25 Edition)

Shots: Welcome to the September edition of Know Your Investor, featuring leading investors fuelling healthcare & life sciences This edition spotlights Cormorant Asset Management, an investment firm focused on biotechnology and healthcare companies In 2024, Cormorant completed 31 investments ~$3.88B, spanning PIPEs, private financings, IPO, and venture rounds. For the full report, contact us at…

ByPrince GiriSeptember 4, 2025

NEWS

Alumis and ACELYRIN Revise Merger Agreement, Boosting ACELYRIN Stake

Shots: Alumis and ACELYRIN have amended their 2025 merger agreement, which originally granted ACELYRIN stockholders 0.4274 Alumis shares/share, giving them a 45% stake in the combined company As per the amendment, ACELYRIN stockholders will receive 0.4814 Alumis shares/share, allowing them to own 48% of the combined entity on a fully diluted basis; closing expected in Q2'25…

ByRidhi RastogiApril 22, 2025

NEWS

Alumis and Kaken Pharmaceutical Enter Collaboration & Licencing Deal for ESK-001’s Development & Commercialization in Japan

Shots: Alumis & Kaken have partnered to develop, manufacture, & market ESK-001 for dermatology in Japan, with an option to expand into rheumatology & GI diseases As per the deal, Kaken will handle development, approval & marketing of ESK-001 in Japan in exchange for $40M upfront & near-term co-development costs, with ~$140M in milestones & field…

ByRidhi RastogiMarch 25, 2025

NEWS

Alumis Signs a Definitive Merger Agreement with ACELYRIN to Develop Novel Therapies for Immune-mediated Diseases

Shots: Alumis & ACELYRIN have entered into a definitive agreement to merge, with ACELYRIN stockholders receiving 0.4274 Alumis shares/share, owning 45% of the combined entity - "Alumis"; closing expected in Q2’25 As of Dec 31, 2024, Alumis & ACELYRIN had ~$289M & ~$448M in cash as well as investments, respectively, with a pro forma…

ByRidhi RastogiFebruary 7, 2025

Know Your Investor: Samsara Biocapital (November’25 Edition)

Know Your Investor: Cormorant Asset Management (September’25 Edition)

Alumis and ACELYRIN Revise Merger Agreement, Boosting ACELYRIN Stake

Alumis and Kaken Pharmaceutical Enter Collaboration & Licencing Deal for ESK-001’s Development & Commercialization in Japan

Alumis Signs a Definitive Merger Agreement with ACELYRIN to Develop Novel Therapies for Immune-mediated Diseases

Contact US

OUR INFORMATION

FOLLOW US